

**CONTACT:** Karen A. Torres  
Cylex, Inc.  
410.964.0236, x140  
[ktorres@cylex.net](mailto:ktorres@cylex.net)

**Cylex™ Ranked 4<sup>th</sup> Fastest Growing Life Sciences Company  
in Greater Washington by Deloitte's 2009 Technology Fast 500™**

***Attributes its Nearly 6x Revenue Growth to Two Leading Factors***

**Columbia, MD USA, October 20, 2009** — Cylex announced that it ranked number 4 among Life Sciences companies in the Greater Washington DC area on Technology Fast 500™, Deloitte LLP's ranking of 500 of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. Rankings are based on percentage of fiscal year revenue growth during the five year period from 2004–2008. Cylex grew 585% during this period.

Cylex's CEO, Brad L. Stewart credits well-characterized technology that is widely accepted in the clinical community as well as an impressive management team with the Company's 585% revenue growth over the past five years. He said, "The expanded commercialization of our technology presents an exciting opportunity for the Company to develop cellular diagnostics for diseases and treatments where the immune system is affected. We have already seen significantly growing demand for our lead product, ImmuKnow®, and are very excited to explore new and better ways Cylex will be able to positively contribute to patient care in the future."

"Technology Fast 500™ recognizes innovative companies that have broken down barriers to success and defied the odds with their remarkable five-year revenue growth," said Phil Asmundson, Vice Chairman and U.S. Technology, Media and Telecommunications leader, Deloitte LLP. "We congratulate Cylex on this accomplishment."

"With its impressive five-year growth, Cylex earned its position among the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America – specifically the Greater Washington area," said Mark Jensen, Managing Partner, Technology and Venture Capital Services, Deloitte & Touche LLP." Deloitte is proud to honor Cylex for its achievement."

Overall, Technology Fast 500™ award winners for 2009 had growth rates ranging from 212 to 146,050 percent over five years, with an average growth rate of 2,486 percent.

**Technology Fast 500™ Selection and Qualifying Criteria**

Technology Fast 500™ provides a ranking of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. This ranking is compiled from nominations submitted directly to the Technology Fast 500™ website, and public company database research conducted

(more)

by Deloitte. Technology Fast 500™ award winners for 2009 are selected based on percentage fiscal year revenue growth during the five year period from 2004 to 2008.

In order to be eligible for Technology Fast 500™ recognition, companies must own proprietary intellectual property or proprietary technology that contributes to a significant portion of the company's operating revenues. Using other companies' technology or intellectual property in a unique way does not satisfy this requirement. Consulting companies, professional service firms, etc. are not eligible unless they have proprietary technology that contributes to a significant portion of their operating revenues.

Technology Fast 500™ award eligibility requirements also include base-year operating revenues of at least \$50,000 USD or CD, and current-year operating revenues of at least \$5 million USD or CD. These revenues must have more than doubled between 2004 and 2008. Additionally, companies must be in business for a minimum of five years, and be headquartered within North America.

#### ***About Cylex, Inc.***

**Cylex** is a privately held global life science company that is the leader in the development and manufacture of *in vitro* diagnostic products. ImmuKnow®, the Company's first FDA cleared product, is sold in 18 countries and used to effectively manage and optimize immunosuppression in organ transplant patients. The Company's patented technology provides an innovative platform allowing clinical researchers to simply and reproducibly measure CMI for the development of new diagnostics, biomarkers and companion assays. The company is based in Columbia, MD USA. For more information, visit [www.cylex.net](http://www.cylex.net).

#### ***About ImmuKnow***

**ImmuKnow** is a noninvasive biomarker of immune function that assesses cellular immune status by detecting cell-mediated immunity (CMI) in adult immunosuppressed patients. It measures the concentration of adenosine triphosphate (ATP) released from CD4 cells following cell stimulation. The ImmuKnow test is a qualitative assay and does not directly quantify the level of immunosuppression. Results of the ImmuKnow assay should be used in conjunction with clinical presentation, medical history, and other clinical indicators when assessing the immune status of any individual patient. For more information, visit [www.cylex.net](http://www.cylex.net).

#### ***About Deloitte***

As used in this document, "Deloitte" means Deloitte LLP. Please see [www.deloitte.com/about](http://www.deloitte.com/about) for a detailed description of the legal structure of Deloitte LLP and its subsidiaries.

###